New insider activity at Idexx Laboratories ( (IDXX) ) has taken place on November 10, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
EVP Nimrata Hunt recently executed a significant transaction by selling 9,425 shares of Idexx Laboratories stock, amounting to a total value of $6,628,983.
Recent Updates on IDXX stock
Idexx Laboratories recently reported strong Q3 financial performance, driven by a 13% revenue increase and a 15% rise in earnings per share. Key growth areas included the CAG Diagnostics segment and international markets, with notable gains in CAG Diagnostics recurring and capital instrument revenues. The company also raised its full-year revenue and EPS guidance, reflecting confidence in its innovation strategy, including the successful launch of new diagnostic tests and increased placements of IDEXX InVue Dx analyzers. Despite challenges such as declining U.S. clinical visits and foreign exchange impacts, the company remains optimistic about future growth. Analyst upgrades, such as Stifel’s, highlight expectations for accelerated CAG recurring revenue growth and the expanding utility of Cancer Dx tests, contributing to a positive outlook.
Spark’s Take on IDXX Stock
According to Spark, TipRanks’ AI Analyst, IDXX is a Outperform.
Idexx Laboratories demonstrates strong financial performance and positive earnings call sentiment, driving the overall score. The technical analysis indicates a strong upward trend, though the high valuation and overbought RSI suggest caution. The company’s strategic focus on innovation and international growth supports its robust outlook.
To see Spark’s full report on IDXX stock, click here.
More about Idexx Laboratories
YTD Price Performance: 73.28%
Average Trading Volume: 462,653
Technical Sentiment Signal: Buy
Current Market Cap: $56.57B